Browsing by Author "Guler, N"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    The effects of the informed consent given for cesarean section on anxiety and knowledge
    Yildirim, G; Cetin, A; Aksu, M; Altiparmak, S; Guler, N
    Purpose: To determine the effects of information given before cesarean section on women's anxiety levels and their knowledge about informed consent regarding it. Materials and Methods: Sixty women who elected to undergo cesarean section were included in the study. The data were collected using the pregnancy-related clinical information form, informed consent form, cesarean information form, and State and Trait Anxiety Inventory. Kruskal-Wallis test, Mann-Whitney U test, chi-square test and Pearson correlation were used as statistical methods. Results: The women's knowledge scores before and after they were informed about cesarean section were 14.8 +/- 5.5 and 29.8 +/- 2.6, respectively (p < 0.05). Their state anxiety scores before and after they were informed about cesarean section were 28.4 +/- 6.6 and 28.0 +/- 5.9, respectively (p > 0.05). Conclusion: It was determined that the participants' pre-training knowledge scores about cesarean section increased significantly after they were informed, and that their state and trait anxiety scores decreased very little after they were informed.
  • No Thumbnail Available
    Item
    Evolution of clinical characteristics of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab in turkey: a multicenter retrospective analysis
    Karadag, FK; Yenerel, MN; Yilmaz, M; Uskudar, H; Ozkocaman, V; Tuglular, TF; Erdem, F; Unal, A; Ayyildiz, O; Ozet, G; Comert, M; Kaya, E; Ayer, M; Salim, O; Guvenc, B; Ozdogu, H; Mehtap, O; Sonmez, M; Guler, N; Hacioglu, S; Aydogdu, I; Bektas, O; Toprak, SK; Kaynar, L; Yagci, M; Aksu, S; Tombak, A; Karakus, V; Yavasoglu, I; Onec, B; Ozcan, MA; Undar, L; Ali, R; Ilhan, O; Saydam, G; Sahin, F
    Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab approved with promising results for PNH patients. We conducted this study to evaluate the long term experience of eculizumab therapy from Turkey for the first time. Our cohort included 138 patients with PNH treated with eculizumab between January 2008 and December 2018 at 28 centers in Turkey. Laboratory and clinical findings at the time of diagnosis and after eculizumab therapy were recorded retrospectively. The median age was 39 (range 18-84) years and median granulocyte PNH clone size was 74% (range 3.06-99.84%) at the time of diagnosis. PNH with bone marrow failure syndrome was detected in 49 patients and the rest of 89 patients had classical PNH. Overall 45 patients (32.6%) had a history of any prior thrombotic event before eculizumab therapy and only 2 thrombotic events were reported during the study period. Most common symptoms are fatigue (75.3%), hemoglobinuria (18.1%), abdominal pain (15.2%) and dysphagia (7.9%). Although PNH is commonly related with coombs negativity, we detected coombs positivity in 2.17% of patients. Seven months after the therapy, increased hemoglobin level was seen and remarkably improvement of lactate dehydrogenase level during the treatment was occurred. In addition to previous studies, our real life data support that eculizumab is well tolerated with no serious adverse events and improves the PNH related findings.